{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:51:09Z","timestamp":1773186669967,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,3]],"date-time":"2020-08-03T00:00:00Z","timestamp":1596412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2020,10,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This is the first-in-human study of novel anti-angiopoietin-2 (Ang-2) monoclonal antibody LY3127804 as monotherapy and in combination with ramucirumab in advanced solid tumours.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients received intravenous LY3127804 monotherapy (4, 8, 12, 16, 20 and 27\u2009mg\/kg) in part A; LY3127804 (8, 12, 16, 20 and 27\u2009mg\/kg) with 8\u2009mg\/kg ramucirumab in part B; and LY3127804 (20\u2009mg\/kg) with 12\u2009mg\/kg ramucirumab in part C. Treatments were administered every 2 weeks (Q2W) during 28-day cycles. Dose-escalation was based on cycle 1 dose-limiting toxicities (DLTs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sixty-two patients were treated in part A (<jats:italic>n<\/jats:italic>\u2009=\u200920), part B (<jats:italic>n<\/jats:italic>\u2009=\u200935) and part C (<jats:italic>n<\/jats:italic>\u2009=\u20097). Constipation, diarrhoea and fatigue were the most common treatment-emergent adverse events (TEAEs) in part A; hypertension and peripheral oedema were the most frequent TEAE in parts B and C. No DLT was observed and maximum tolerated dose for LY3127804 was not reached. Four patients achieved partial response with combination therapy (clear cell endometrial carcinoma, cervix squamous cell carcinoma, carcinoma of unknown primary and gastroesophageal junction carcinoma), 29 achieved stable disease, and 24 had progressive disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>LY3127804 monotherapy and its combination with ramucirumab are well tolerated. LY3127804 20\u2009mg\/kg was the recommended Phase 2 dose.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-020-1011-7","type":"journal-article","created":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T23:02:23Z","timestamp":1596409343000},"page":"1235-1243","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["First-in-human, dose-escalation, phase 1 study of anti-angiopoietin-2 LY3127804 as monotherapy and in combination with ramucirumab in patients with advanced solid tumours"],"prefix":"10.1038","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2552-5172","authenticated-orcid":false,"given":"Juan","family":"Martin-Liberal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Jungels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Martin-Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill Dolores","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Bendell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,3]]},"reference":[{"key":"1011_CR1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya, M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2, 1097\u20131105 (2011).","journal-title":"Genes Cancer"},{"key":"1011_CR2","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-09-2797","volume":"16","author":"NR Smith","year":"2010","unstructured":"Smith, N. R., Baker, D., James, N. H., Ratcliffe, K., Jenkins, M., Ashton, S. E. et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin. Cancer Res. 16, 3548\u20133561 (2010).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR3","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10456-017-9552-y","volume":"20","author":"RR Ramjiawan","year":"2017","unstructured":"Ramjiawan, R. R., Griffioen, A. W. & Duda, D. G. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis 20, 185\u2013204 (2017).","journal-title":"Angiogenesis"},{"key":"1011_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","volume":"328","author":"E Fagiani","year":"2013","unstructured":"Fagiani, E. & Christofori, G. Angiopoietins in angiogenesis. Cancer Lett. 328, 18\u201326 (2013).","journal-title":"Cancer Lett."},{"key":"1011_CR5","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1200\/JCO.2008.19.6683","volume":"27","author":"RS Herbst","year":"2009","unstructured":"Herbst, R. S., Hong, D., Chap, L., Kurzrock, R., Jackson, E., Silverman, J. M. et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol. 27, 3557\u20133565 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1011_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clgc.2013.11.007","volume":"12","author":"DS Hong","year":"2014","unstructured":"Hong, D. S., Gordon, M. S., Samlowski, W. E., Kurzrock, R., Tannir, N., Friedland, D. et al. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer 12, 167\u201377 e2 (2014).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1011_CR7","doi-asserted-by":"publisher","first-page":"11154","DOI":"10.18632\/oncotarget.2568","volume":"5","author":"DS Hong","year":"2014","unstructured":"Hong, D. S., Kurzrock, R., Mulay, M., Rasmussen, E., Wu, B. M., Bass, M. B. et al. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget 5, 11154\u201311167 (2014).","journal-title":"Oncotarget"},{"key":"1011_CR8","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1158\/1078-0432.CCR-17-1775","volume":"24","author":"DM Hyman","year":"2018","unstructured":"Hyman, D. M., Rizvi, N., Natale, R., Armstrong, D. K., Birrer, M., Recht, L. et al. Phase I study of MEDI3617, a selective angiopoietin-2 inhibitor alone and combined with carboplatin\/paclitaxel, paclitaxel, or bevacizumab for advanced solid tumors. Clin. Cancer Res. 24, 2749\u20132757 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1158\/1078-0432.CCR-15-1221","volume":"22","author":"KP Papadopoulos","year":"2016","unstructured":"Papadopoulos, K. P., Kelley, R. K., Tolcher, A. W., Razak, A. R., Van Loon, K., Patnaik, A. et al. A phase I first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors. Clin. Cancer Res. 22, 1348\u20131355 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2016.09.004","volume":"70","author":"C Marth","year":"2017","unstructured":"Marth, C., Vergote, I., Scambia, G., Oberaigner, W., Clamp, A., Berger, R. et al. ENGOT-ov-6\/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. Eur. J. Cancer 70, 111\u2013121 (2017).","journal-title":"Eur. J. Cancer"},{"key":"1011_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ygyno.2016.07.112","volume":"143","author":"BJ Monk","year":"2016","unstructured":"Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D. S. et al. Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. Gynecol. Oncol. 143, 27\u201334 (2016).","journal-title":"Gynecol. Oncol."},{"key":"1011_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/S1470-2045(19)30178-0","volume":"20","author":"I Vergote","year":"2019","unstructured":"Vergote, I., Scambia, G., O\u2019Malley, D. M., Van Calster, B., Park, S. Y., Del Campo, J. M. et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3\/ENGOT-ov2\/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 20, 862\u2013876 (2019).","journal-title":"Lancet Oncol"},{"key":"1011_CR13","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1158\/0008-5472.CAN-12-4697","volume":"73","author":"D Gerald","year":"2013","unstructured":"Gerald, D., Chintharlapalli, S., Augustin, H. G. & Benjamin, L. E. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 73, 1649\u20131657 (2013).","journal-title":"Cancer Res."},{"issue":"(14 Suppl)","key":"1011_CR14","first-page":"Abstract nr 325","volume":"76","author":"R Sudhakar","year":"2016","unstructured":"Sudhakar, R., Chintharlapalli, J. E. C., Leung, D., Gerald, D., Lu, J., Iversen, P. W., Lee, L. N., Huber, L., Tetreault, J., Almonte-Baldonado, R., Xu, J., Ramamurthy, B., Pereira, J. A., Chow, C-H., Hanauske, A-R., Wacheck, V., Benjamin, L. & Liu, L. LY3127804, a novel anti-Angiopoietin-2 antibody in combination with an anti-VEGFR2 antibody potently inhibits angiogenesis, tumor growth and metastasis. Cancer Res. 76, (14 Suppl) Abstract nr 3259 (2016).","journal-title":"Cancer Res"},{"key":"1011_CR15","unstructured":"A study of LY3127804 with ramucirumab in participants with advanced solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02597036 (2019)."},{"key":"1011_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"1011_CR17","unstructured":"SERVICES USDOHAH. Common terminology criteria for adverse events (CTCAE) version 4.0. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (2009)."},{"key":"1011_CR18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"1011_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ygyno.2014.07.003","volume":"135","author":"I Vergote","year":"2014","unstructured":"Vergote, I., Schilder, R. J., Pippitt, C. H. Jr., Wong, S., Gordon, A. N., Scudder, S. et al. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Gynecol. Oncol. 135, 25\u201333 (2014).","journal-title":"Gynecol. Oncol."},{"key":"1011_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00280-012-2000-1","volume":"71","author":"T Doi","year":"2013","unstructured":"Doi, T., Ohtsu, A., Fuse, N., Yoshino, T., Tahara, M., Shibayama, K. et al. Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1\/2 antagonist, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol. 71, 227\u2013235 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1011_CR21","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1158\/1078-0432.CCR-16-2882","volume":"23","author":"SES Leary","year":"2017","unstructured":"Leary, S. E. S., Park, J. R., Reid, J. M., Ralya, A. T., Baruchel, S., Wu, B. et al. Pediatric phase I trial and pharmacokinetic study of trebananib in relapsed solid tumors, including primary tumors of the central nervous system ADVL1115: A Children\u2019s Oncology Group Phase I Consortium Report. Clin. Cancer Res. 23, 6062\u20136069 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR22","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-15-2145","volume":"22","author":"A Dowlati","year":"2016","unstructured":"Dowlati, A., Vlahovic, G., Natale, R. B., Rasmussen, E., Singh, I., Hwang, Y. C. et al. A phase I, first-in-human study of AMG 780, an angiopoietin-1 and -2 inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 22, 4574\u20134584 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR23","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1158\/1078-0432.CCR-17-1588","volume":"24","author":"M Hidalgo","year":"2018","unstructured":"Hidalgo, M., Martinez-Garcia, M., Le Tourneau, C., Massard, C., Garralda, E., Boni, V. et al. First-in-human phase I study of single-agent vanucizumab, a first-in-class bispecific anti-angiopoietin-2\/anti-VEGF-A antibody, in adult patients with advanced solid tumors. Clin. Cancer Res. 24, 1536\u20131545 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1011_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G. & Jain, R. K. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325\u2013340 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1011_CR25","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3389\/fimmu.2018.03120","volume":"9","author":"A Amin","year":"2018","unstructured":"Amin, A. & Hammers, H. The evolving landscape of immunotherapy-based combinations for frontline treatment of advanced renal cell carcinoma. Front. Immunol. 9, 3120 (2018).","journal-title":"Front. Immunol."},{"key":"1011_CR26","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.2147\/OTT.S178497","volume":"11","author":"H Liang","year":"2018","unstructured":"Liang, H., Liu, X. & Wang, M. Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. Onco Targets Ther. 11, 6189\u20136196 (2018).","journal-title":"Onco Targets Ther."},{"key":"1011_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","volume":"19","author":"MB Atkins","year":"2018","unstructured":"Atkins, M. B., Plimack, E. R., Puzanov, I., Fishman, M. N., McDermott, D. F., Cho, D. C. et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 19, 405\u2013415 (2018).","journal-title":"Lancet Oncol."},{"key":"1011_CR28","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116\u20131127 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR29","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","volume":"380","author":"RJ Motzer","year":"2019","unstructured":"Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103\u20131115 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1011_CR30","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","volume":"393","author":"BI Rini","year":"2019","unstructured":"Rini, B. I., Powles, T., Atkins, M. B., Escudier, B., McDermott, D. F., Suarez, C. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393, 2404\u20132415 (2019).","journal-title":"Lancet"},{"key":"1011_CR31","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","volume":"23","author":"HT Arkenau","year":"2018","unstructured":"Arkenau, H. T., Martin-Liberal, J., Calvo, E., Penel, N., Krebs, M. G., Herbst, R. S. et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase I trial (JVDF). Oncologist 23, 1407\u2013e136 (2018).","journal-title":"Oncologist"},{"key":"1011_CR32","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S1470-2045(19)30458-9","volume":"20","author":"AH Herbst RS","year":"2019","unstructured":"Herbst RS, A. H., Santana-Davilla, R., Calvo, E., Paz-Ares, L., Cassier, P. A. et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial. Lancet Oncol. 20, 1109\u20131123 (2019).","journal-title":"Lancet Oncol."},{"key":"1011_CR33","doi-asserted-by":"crossref","unstructured":"Rahma, O.E. C. J., Schlechter, B. M., Ng, K., Eno, J., Stroiney, A., Giobbie-Hurder, A., McDermott, D. F., Hodi, F. S. Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): preliminary analysis of the colorectal cancer (CRC) cohort. J. Clin. Oncol. 37, 15_suppl, e14160\u2013e14160 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.e14160"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-1011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-1011-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-1011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,3]],"date-time":"2021-08-03T00:07:18Z","timestamp":1627949238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-020-1011-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,3]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,10,13]]}},"alternative-id":["1011"],"URL":"https:\/\/doi.org\/10.1038\/s41416-020-1011-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,3]]},"assertion":[{"value":"2 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review boards of each centre approved the study protocol before initiation of patient enrolment (Supplementary Table\u00a0). The study adhered to the Declaration of Helsinki, the International Conference on Harmonization Guidelines for Good Clinical Practice, Council for International Organizations of Medical Sciences, and applicable local regulations. All patients provided informed consent before enrolment. The study was registered in ClinicalTrials.gov (NCT02597036).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Lilly provides access to all individual participant data collected during the trial, after anonymisation, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once they are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data-sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report and blank or annotated case report forms, will be provided in a secure data-sharing environment for up to 2 years per proposal. For details on submitting a request, see the instructions provided at .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"J.M.L. received lecture fees from Astellas Pharma, Bristol\u2013Myers Squibb, Merck Sharp & Dohme (MSD), Novartis, Pierre Fabre, Pfizer, and Roche; advisory fees from Bristol\u2013Myers Squibb, MSD, Novartis, Pierre Fabre, and Roche; and travel grants from Bristol\u2013Myers Squibb, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Ipsen. A.H. received honoraria\/advisory fees from Gritstone Oncology, Eisai Co., Ltd., Amgen, Servier and Merck Serono. P.A. received honoraria\/advisory fees from Novartis, Roche, MacroGenics, G1 Therapeutics, Servier, Synthon, Amcure, Amgen and Boehringer Ingelheim; and travel grants from MSD, Pfizer and Roche. C.J. received travel grants from PharmaMar S.A., Bayer and Ipsen. P Martin-Romano: Principal\/sub-Investigator of Clinical Trials for AbbVie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, AstraZeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol\u2013Myers Squibb, Bristol\u2013Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited, Eli Lilly, Exelixis, Forma Therapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kgaa, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth Pharmaceuticals France, Xencor, Y\u2019s Therapeutics, Research Grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. P Martin-Romano also disclosed non-financial support (drug supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH TherAGuiX, Pfizer, Roche. J.R.A. received personal fees and other from Novartis, Kelun Pharmaceuticals\/Klus Pharma, Spectrum Pharmaceuticals Inc, Pfizer, Bayer. Personal fees from Eli Lilly and Company, Orion Pharmaceuticals, Roche Pharmaceuticals, Ellipses Pharma, Certera, Ionctura SA. Also conflict with European Journal of Cancer, VHIO\/Ministero De Empleo Y Seguridad Social, Chinese University of Hong Kong, SOLTI, Elsevier, GlaxoSmithKline, ESMO, Department of Defense, Merck Sharp & Dohme, Louisiana State University, Huntsman Cancer Institute, Cancer Core Europe, Karolinska Cancer Institute, King Abdullah International Medical Research Center, WIN Consortium, Janssen, Tocagen, Symphogen, BioAlta, GenMab, CytomX, Kelun-Biotech, Takea-Millenium, and Ipsen. J.D.K. and W.Z. are employees and stockholders in Eli Lilly and Company. J.B. received grants and other from Gilead, Genentech\/Roche, BMS, Five Prime, Eli Lilly and Company, Merck, MedImmune, Celgene, Taiho, Macrogenics, GlaxoSmithkline, Novartis, OncoMed, LEAP, TG Therapeutics, AstraZeneca, BI, Daiichi Sankyo, Bayer, Incyte, Apexigen, Array, Sanofi, Agios, Ipsen, Merrimack, Oncogenex, Evelo, Forma, Innate, Arch Oncology, Prelude Therapeutics, Amgen, Seattle Genetics, Bicycle Therapeutics, and Relay Therapeutics. Received grants from EMD Serono, Koltan, SynDev Rex, Abbvie, Onyx, Takeda, EISAI, Celldex, Xytomx, Nektar, Armo, Boston Biomedical, Tarveda, Tyrogenex, Marshall Edwards, Pieris, Mersana, Calithera, Blueprint, Merus, Effector, Novocare, Arrys, Tracon, Sierra, Jacobio, Unum Therapeutics, Vyriad, Harpoon, ADC, Pfizer, Millennium, Imclome, Acerta Pharma, Rgenix, Bellicum, Gossamer Bio, Arcus Bio, Tempest Tx, Shattuck Labs, Synthorx, Inc, Revolution Medicines, Inc, and Zymework. Conflict with Phoenix Bio, Cyteir, Molecular Partners, Torque, Tizona, Janssen, Tolero, TD2 (Translational Drug Development), Moderna Therapeutics, Tanabe Research Laboratories, Beigene and Continuum Clinical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was sponsored by Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}